SCHEMBL4479986

SCHEMBL4479986

COc1cc(Br)cc(CN2C(=O)COc3cc(OC)ccc32)c1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.59
CBX7 O95931 1/20 0.44
CDYL2 Q8N8U2 1/20 0.44
CDYL Q9Y232 1/20 0.44
CDY1; CDY1B Q9Y6F8 1/20 0.44
ALDH1A1 P00352 1/20 0.44
BRD4 O60885 1/20 0.42
SMPD1 P17405 1/20 0.41
F10 P00742 2/20 0.41
MAPT P10636 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PIK3CG P48736 2/20 0.39
SLC5A1 P13866 1/20 0.39
SLC5A2 P31639 1/20 0.39
CMA1 P23946 1/20 0.39
PARK7 Q99497 1/20 0.39
CHRM1 P11229 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4477873 0.90 L3MBTL1 (0.58) L3MBTL1CBX7CDYL2CDYLCDY1; CDY1B
SCHEMBL6096108 0.79 L3MBTL1 (0.72) L3MBTL1CBX7CDYL2CDYLCDY1; CDY1B
SCHEMBL22407571 0.78 L3MBTL1 (0.60) L3MBTL1CBX7CDYL2CDYLCDY1; CDY1B
SCHEMBL10849516 0.78 L3MBTL1 (0.53) L3MBTL1CBX7CDYL2CDYLCDY1; CDY1B
SCHEMBL15176632 0.78 L3MBTL1 (0.70) L3MBTL1ALDH1A1BRD4SMPD1F10
SCHEMBL6096494 0.78 L3MBTL1 (0.70) L3MBTL1CBX7CDYL2CDYLCDY1; CDY1B
SCHEMBL25685666 0.76 L3MBTL1 (0.58) L3MBTL1CBX7CDYL2CDYLCDY1; CDY1B
SCHEMBL20782632 0.76 L3MBTL1 (0.58) L3MBTL1CBX7CDYL2CDYLCDY1; CDY1B
SCHEMBL15874599 0.76 L3MBTL1 (0.72) L3MBTL1ALDH1A1BRD4SMPD1MAPT
SCHEMBL2948381 0.76 TSHR (0.60) L3MBTL1CBX7CDYL2CDYLCDY1; CDY1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7476675-B2 Quinolinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2009-01-13 US disclosed
US-7476675-B2 Quinolinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2009-01-13 US disclosed
EP-1603880-B1 QUINOLINONE/BENZOXAZINONE DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2008-05-07 EP disclosed
US-20050261308-A1 Quinolinone derivatives and uses thereof ROCHE PALO ALTO LLC 2005-11-24 US disclosed
US-6943169-B2 Quinolinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2005-09-13 US disclosed
US-20040186092-A1 Quinolinone derivaties and uses thereof ROCHE PALO ALTO LLC 2004-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186092-A1 Quinolinone derivaties and uses thereof NQO2, UGT1A8, UGT1A1 L3MBTL1 4557/4885CBX7 360/4885CDYL2 1889/4885
US-20050261308-A1 Quinolinone derivatives and uses thereof RECQL, NQO2, QRFPR L3MBTL1 4043/4885CBX7 389/4885CDYL2 2485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.